A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Completed · Phase 1/Phase 2

Conditions studied: Influenza Immunization, Healthy Volunteers

In brief

The purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Key facts

Study ID

NCT06361875

Run by

Sanofi Pasteur, a Sanofi Company

People needed

908

Starts

2024-04-01

Expected to finish

2025-06-09

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged from 18 years on the day of inclusion or aged from 21 years on the days of inclusion, depending on the countries.
• A female participant was eligible to participate if she was not pregnant or breastfeeding and one of the following conditions applied:
• Was of non-childbearing potential. To be considered of non-childbearing potential, a female must of been postmenopausal for at least 1 year, or surgically sterile OR
• Was of childbearing potential and agreed to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.
• A female participant of childbearing potential must of had a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the 1st dose of study intervention
• Exclusion Criteria: Participants were excluded from the study if any of the following criteria applied:
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA vaccine
• Previous history of myocarditis, pericarditis, and / or myopericarditis
• Known history of previous episodes of Gillian-Barre Syndrome (GBS), neuritis (including Bell's palsy), convulsions, encephalitis, transverse myelitis, and vasculitis
• Participants with an ECG that is consistent with possible myocarditis or pericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
• Self-reported thrombocytopenia, contraindicating Intramuscular vaccination based on Investigator's judgment
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating Intramuscular vaccination based on Investigator's judgment
• Chronic illness that, in the opinion of the Investigator, was at a stage where it might have interfered with study conduct or completion
• Moderate or severe acute illness / infection (according to Investigator's judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccination. A prospective participant was not included in the study until the condition was resolved or the febrile event subsided
• Participant who had acute infection symptoms or a positive SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior to the 1st visit (V01)
• Receipt of any vaccine in the 4 weeks preceding study intervention administration or planned receipt of any vaccine in the 4 weeks following study intervention administration
• Receipt of immune globulins, blood or blood-derived products in the past 3 months
• Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine
• Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration
• NOTE: The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• California Research Foundation Site Number : 8400038 — San Diego, California, United States
• Indago Research and Health Center- Site Number : 8400032 — Hialeah, Florida, United States
• Cenexel Research Centers of America- Site Number : 8400037 — Hollywood, Florida, United States
• Brengle Family Medicine Site Number : 8400045 — Indianapolis, Indiana, United States
• AMR Lexington- Site Number : 8400042 — Lexington, Kentucky, United States
• Velocity Clinical Research- New Orleans Site Number : 8400053 — New Orleans, Louisiana, United States
• The Alliance for Multispecialty Research - KCM, LLC- Site Number : 8400034 — Kansas City, Missouri, United States
• Velocity Clinical Research Norfolk- Site Number : 8400046 — Norfolk, Nebraska, United States
• AMR Knoxville- Site Number : 8400043 — Knoxville, Tennessee, United States
• Clinical Trials of Texas, Inc. - PPDS- Site Number : 8400029 — San Antonio, Texas, United States
• Cenexel JBR- Site Number : 8400051 — Salt Lake City, Utah, United States
• Investigational Site Number : 3400001 — San Pedro Sula, Honduras
• Investigational Site Number : 6300002 — Barrio Sabana, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.